JAMA Dermatology has published a pilot study demonstrating the safety and efficacy of intermittent intravenous methylprednisolone pulse (IVMP) therapy plus mycophenolate in 28 patients with juvenile dermatomyositis (JDM).
Read Article
Dr. Jack Cush reviews the journal articles, news and guidelines from this past week on RheumNow.com
Read Article
A cohort study shows that hospitalized patients with dermatomyositis have higher in-hospital mortality in the presence of active rash, interstitial lung disease, and elevated neutrophil to lymphocyte ratio at admission.
Dermatomyositis (DM) has significiant
#ACR25 Abstr#LB14 Promising therapy BMS-986353, a CD19 CAR-T in Severe Refractory Idiopathic Inflammatory Myopathies. 11/12 had evaluable data; muscle, skin and ILD improved. 1 x G2 CRS, 1 G3 ICANS. Longer FU needed and larger sample @RheumNow https://t.co/zAG23tAsbL
Links:
Links:
Dr. Jack Cush reviews the news, FDA approvals, and journal articles. In this episode: HMGCR Abs, FDA approvals and Cush eats crow.
Read Article
Whole-body MRI (wbMRI) reviews have increasingly appeared in the medical literature, owing to better scanners, faster imaging times and reduced costs. Used of such non-oncologic musculoskeletal imaging provides high-contrast resolution images of the entire body or selected regions screening,
Read Article
Dr. Jack Cush reviews the news, journal reports and important associations in rheumatology from the past week on RheumNow.com.
Read Article
Children with juvenile idiopathic inflammatory myositis (JIIM) are at risk of developing lung disease, notably interstitial lung disease (ILD). ILD can be asymptomatic initially, progressing silently to irreversible lung damage, which underscores the importance of early detection
Read Article
A systematic review and meta-analysis examined the role of high-resolution computed tomography (HRCT) in diagnosing and characterizing interstitial lung disease (ILD) associated with connective tissue diseases (CTDs). The study analyzed 23 studies published between 2015-2024,
When idiopathic inflammatory myopathies (IIM) affect the lungs, the consequences can be serious. ILD is not only common in IIM, but also one of the leading causes of death, contributing to up to 80% of mortality in this patient group. For rheumatologists, two subsets stand out: anti-synthetase
Read Article
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Are there benefits to diet or vegan diets? What's the effect of menopause on CTD? Ro52 makes a big entrance with all our ILD coverage this month.
Read Article
The European Respiratory Society (ERS) and European Alliance of Associations for Rheumatology (EULAR) have published clinical practice guidelines for the evaluation and management of connective tissue diseases (CTD) associated interstitial lung disease (ILD) in two simultaneous publications in
Read Article
Dr. Jack Cush reviews the news and journal reports from RheumNow. This week - unemployment, diagnosing Sjogren's and a lot of ILD.
Read Article
Dr. Jack Cush reviews the news, journal reports, FDA approvals, drug safety, and more from this week.
Read Article
A current Cochrane review suggests a continued unmet need regarding the status and utility of targeted immunosuppressant and immunomodulatory treatments for the idiopathic inflammatory myopathies (IIM). Overall there has been little progress since the previous Cochrane review (2012) that found
Read Article
Researchers from the University of Pennsylvania have published an open-access review of dermatomyositis (DM) - its manifestations, hallmark cutaneous features, etiopathogenesis and treatment options.
Read Article
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com along with interesting case questions from "Ask Cush Anything".
Read Article
Dr. Jack Cush reviews the news and journal reports from this past week - some obvious, other new thoughts and some - hmmm, reallly?
Read Article
Links:
Winning is everything – in football and in medicine. Rheumatologists have achieved many successes but still struggle to win against a handful of rheumatic foes. This retrospective examines past wins and losses and helps us to look ahead to a new season.
Read PostBy downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
